Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

The Week in Review: More CRO Consolidation

publication date: Jul 10, 2010
 | 
author/source: Richard Daverman, PhD
Venturepharm Laboratory announced the signing of a letter of intent with a “large leading multinational healthcare company” to form a joint venture (see story). The independent third party will own a 70% stake in the clinical stage CRO JV. No dollar amounts were mentioned, nor was the name of the company released. Venturepharm did say it would contribute its clinical research business to the JV.

The biggest 100 pharmaceutical manufacturers in China produced revenues of 339 billion RMB in 2009 ($50 billion), a 25% increase from the year earlier (see story). The top 100 accounted for 42% of the drug market, a year-over-year rise of 1.4%. The total market for drugs, meanwhile, climbed only 20.8%.

China Animal Healthcare (SI: CAHC), a Singapore-listed company, raised $45 million in new capital from an investor group led by the US private equity heavyweight Blackstone Group (NYSE: BX) (see story). China Animal Healthcare will use the proceeds to expand its vaccine business, make acquisitions or buy back shares.

Artepharm Global Corp. (OTCBB: ARGC) announced a $10 million effort to eradicate malaria in East Africa’s Comoros Islands (see story). The effort will use Artepharm’s patented ArteQuick Malaria treatment, an inexpensive four-pill treatment based on a TCM, artemisinin, which has been used for centuries to treat malaria.

HEGLN (Dalian) Pharmaceutical, a China biotech company, paid $2 million (US) to acquire the uroNIRS technology from Urodynamix Technologies (TSX Venture: URO) of Canada (see story). The uroNIRS machines use near-infrared spectroscopy (NIRS) as a non-invasive means of diagnosing urologic conditions.

Swedish Orphan Biovitrum (STO: SOBI) will set up a strategic commercial alliance with Tonghua Dongbao Pharma Co Ltd. (SHEX: 600867) (see story). Under the terms of the agreement, each company will become the “sales partner of choice” for products from the other entity.


Disclosure: none.




 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital